Plymouth, MI (June 13, 2017) – Genetic analysis and variant interpretation has come a long way. However, to make this science a viable option for patient care, it is required for companies to make this data HIPAA compliant, easily readable, understandable and accessible to healthcare professionals. Advaita Bioinformatics has become of the first companies to make their cloud-based product available in a HIPAA compliant environment. Its iVariantGuide is the next-generation software suite for genetic variant analysis that brings precision and personalized medicine one step closer to everyday clinical practice. Advaita announced today that the newly-released iVariantGuide now meets all of the standards set forth by US Health Insurance Portability and Accountability Act (HIPAA), the law that ensures the privacy and security of patients’ medical records, including data from Next-Gen Sequencing (NGS) and other genetic analyses. With HIPAA compliance, Advaita’s bioinformatics platform may now be used with genetics tests for cancer treatment as well as genetic screening for diabetes, rare diseases, and many more conditions.

With this move, Advaita has poised itself to become a dominant player in the Genetic Interpretation and Analysis market, which is one of the fastest-growing segments in the Healthcare arena.

“Healthcare professionals are facing a daunting task fighting diseases such as cancer, obesity, diabetes and Alzheimer’s.” says Dr. Sorin Draghici, CEO of Advaita. “We wanted to provide them with the tools they need to make definitive diagnoses. If they can understand the genetic characteristics of the patient, a whole new arsenal of targeted treatments becomes available, allowing the doctors to tailor treatments to their individual patients. Our genetic interpretation and analysis tool makes this possible with its easy-to-understand report, which provides a comprehensive understanding in a much shorter time. This represents a unique and innovative way for these professionals to get their patients on the right path to improved health.”

To make precision medicine a reality for all patients, we need an easier and faster way to identify the important genetic variants that make each person an individual. With this announcement, Advaita leads this charge and enters into the vast clinical market. This next step is helping change the way medical professionals use genetics in their day-to-day analysis, help them identify problems faster, and provide the tools required to tackle these diseases in a more precise and effective manner. It will surely help accelerate the way genetic data is being interpreted, adopted and utilized.”

About Advaita Bioinformatics:
Advaita Bioinformatics is a leader in the interpretation of high-throughput biomedical data including variant interpretation, pathway analysis, disease subtype discovery and integration of multiple data types. Currently, 9 of the top 10 pharma companies rely on Advaita’s state-of-the-art algorithms to solve complex problems. Advaita was founded by Sorin Draghici, a professor at Wayne State University, and provides a suite of advanced analysis software to more that 10,000 registered users worldwide: iPathwayGuide, for functional interpretation of genes and proteins; iVariantGuide, for genetic variant analysis; and iBioGuide, a search engine revealing connections between genes, pathways, SNPs, drugs, and more.